Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-NaF PET/CT in Enzalutamide-Treated mCRPC
NCT02384382Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Pfizer. Primary endpoint: Percentage of Participants With at Least 1 Responding Bone Lesion Assessed by Total Sodium Fluoride (NaF) Standardized Uptake Value [SUVtotal] up to 34.1 months. Started Nov 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02384382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384382.